Janssen Biotech discontinued development of its CD20/CD19 CAR T bispecific, prompting Abelzeta Pharma to regain worldwide rights to prizloncabtagene autoleucel (C-CAR039). The rights transfer excludes China, where Janssen previously retained elements of the arrangement. Abelzeta and Shanghai partners originally licensed the therapy from Janssen in 2023 in a deal reported at $245 million, covering global commercialization and development rights for C-CAR039 and related anti-CD20 CAR T programs. Janssen’s decision to stop development marks a significant portfolio contraction for the company in CAR T. For Abelzeta, the key question becomes whether the therapy can re-enter development with renewed timelines, updated manufacturing strategy, and clearer clinical positioning to avoid further dilution of progress.